Psychopharmacology of autism spectrum disorders;Psychopharmakologie autistischer störungen

Nervenarzt

Volumn 82, Issue 5, 2011, Pages 582-589

  Poustka, L ^a   Banaschewski, T ^a   Poustka, F ^b  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b Privatpraxis Facharzt Zentrum Frankfurt City   (Germany)

Author keywords

Aggression; Atypical antipsychotic agents; Autism; Comorbidity; Psychopharmacology

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

AUTISM; COMORBIDITY; DRUG EFFICACY; PSYCHOPHARMACOLOGY; REVIEW;

EID: 79960029313     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-010-3238-7     Document Type: Review

References (56)

1. Aman MG, Hollway JA, McDougle CJ et al (2008) Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 18:227-236
2. Aman MG, McDougle CJ, Scahill L et al (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry (Epub ahead of print)
3. Andersen IM, Kaczmarska J, McGrew SG, Malow BA (2008) Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 23:482-485 (Pubitemid 351566859)
4. Arnold LE, Aman MG, Cook AM et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196-1205 (Pubitemid 44465640)
5. Arnold LE, Vitiello B, McDougle C et al (2003) Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 42:1443-1450 (Pubitemid 39585974)
6. Belsito KM, Law PA, Kirk KS et al (2001) Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31:175-181 (Pubitemid 37490163)
7. Bent S, Bertoglio K, Ashwood P et al (2010) A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord (in press)
8. Bethea TC, Sikich L (2007) Early pharmacological treatment of autism: a rationale for developmental treatment. Biol Psychiatry 61:521-537 (Pubitemid 46185342)
9. Chadman KK (2011) Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism. Pharmacol Biochem Behav 97:586-594
10. Croonenberghs J, Wauters A, Deboutte D et al (2007) Central serotonergic hypofunction in autism: results of the 5-hydroxy-tryptophan challenge test. Neuro Endocrinol Lett 28:449-455 (Pubitemid 47577725)
11. Di Martino A, Melis G, Cianchetti C, Zuddas A (2004) Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 14:207-218 (Pubitemid 38988787)
12. Ellis CR, Singh NN, Ruane AL (1999) Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities. Ment Retard Dev Disabil Res Rev 5(4):335-341 (Pubitemid 30033622)
13. Erickson CA, Posey DJ, Stigler KA et al (2007) A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 191:141-147 (Pubitemid 46294942)
14. Fankhauser MP, Karumanchi VC, German ML et al (1992) A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53:77-82
15. Findling RL (2005) Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. J Clin Psychiatry 66(Suppl 10):26-31
16. Garstang J, Wallis M (2006) Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 32:585-589 (Pubitemid 44210097)
17. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P (2006) An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 36:741-752 (Pubitemid 44284978)
18. Green JJ, Hollander E (2010) Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics 7:250-257
19. Guastella AJ, Einfeld SL, Gray KM et al (2010) Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 67:692-694
20. Guastella AJ, Mitchell PB, Dadds MR (2008) Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 63:3-5 (Pubitemid 350234895)
21. Handen BL, Johnson CR, Lubetsky M (2000) Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245-255
22. Hollander E, Bartz J, Chaplin W et al (2007) Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61:498-503 (Pubitemid 46185336)
23. Hollander E, Chaplin W, Soorya L et al (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 35:990-998
24. Hollander E, Novotny S, Hanratty M et al (2003) Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 28:193-198
25. Hollander E, Phillips A, Chaplin W et al (2005) A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582-589 (Pubitemid 40271160)
26. Hollander E, Wasserman S, Swanson EN et al (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16:541-548 (Pubitemid 44737209)
27. Holtmann M, Bölte S, Poustka F (2006) Genetik des Autismus. Med Genet 18:170-174 (Pubitemid 44146051)
28. Jahromi LB, Kasari CL, McCracken JT et al (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 39:395-404
29. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL (1992) Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322-327
30. King BH, Bostic JQ (2006) An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 15:161-175 (Pubitemid 41735242)
31. King BH, Hollander E, Sikich L et al (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66:583-590
32. Leyfer OT, Folstein SE, Bacalman S et al (2006) Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 36:849-861 (Pubitemid 44440104)
33. Marcus RN, Owen R, Kamen L et al (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119
34. Martin A, Scahill L, Anderson GM et al (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125-1127 (Pubitemid 38736004)
35. McCracken JT (2005) Safety issues with drug therapies for autism spectrum disorders. J Clin Psychiatry 66(Suppl 10):32-37
36. McDougle CJ, Naylor ST, Cohen DJ et al (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008 (Pubitemid 26384669)
37. McDougle CJ, Scahill L, Aman MG et al (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142-1148 (Pubitemid 40770697)
38. Meyer-Lindenberg A (2008) Impact of prosocial neuropeptides on human brain function. Prog Brain Res 170:463-470
39. Owen R, Sikich L, Marcus RN et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533-1540
40. Owley T, McMahon W, Cook EH et al (2001) Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry 40:1293-1299 (Pubitemid 32995797)
41. Owley T, Salt J, Guter S et al (2006) A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:517-524 (Pubitemid 44737207)
42. Penzner JB, Dudas M, Saito E et al (2009) Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19:563-573
43. Posey DJ, Kem DL, Swiezy NB et al (2004) A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 161:2115-2117 (Pubitemid 39441414)
44. Posey DJ, Puntney JI, Sasher TM et al (2004) Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233-241 (Pubitemid 38988789)
45. Posey DJ, Wiegand RE, Wilkerson J et al (2006) Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:599-610 (Pubitemid 44739916)
46. Poustka F (2007) Neurobiology of autism. In: Volkmar F (Hrsg) Autism and pervasive developmental disorders. 2. Aufl. Univ Press, Cambridge, S 179-220
47. Poustka L, Poustka F (2009) Psychopharmakologie autistischer Störungen. In: Bölte S (Hrsg) Autismus Spektrum: Ursachen, Diagnostik, Intervention, Perspektiven. Huber, Bern, S 387-399
48. RUPP Autism Network (2005) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274
49. RUPP Autism Network (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361-1369
50. Santosh PJ, Baird G, Pityaratstian N et al (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 32:575-583 (Pubitemid 44210096)
51. Simonoff E, Pickles A, Charman T et al (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47:921-929
52. Troost PW, Steenhuis MP, Tuynman-Qua HG et al (2006) Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 16:611-619 (Pubitemid 44737214)
53. Tuchman R, Alessandri M, Cuccaro M (2010) Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment. Brain Dev 32:719-730
54. Wasdell MB, Jan JE, Bomben MM et al (2008) A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 44:57-64 (Pubitemid 350231110)
55. Wewetzer C, Mehler-Wex C, Warnke A (2003) Pharmacotherapy of compulsive disorders in childhood and adolescence. Z Kinder Jugendpsychiatr Psychother 31:223-230 (Pubitemid 36958606)
56. Willemsen-Swinkels SH, Buitelaar JK, Engeland H van (1996) The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 39:1023-1031 (Pubitemid 26191350)